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ABSTRACT 
INTRODUCTION: Several studies have shown differences in survival trends between 
ethnic groups across adults with cancer in the UK. It is unclear whether these differences 
exist exclusively in the older adult population or whether they begin to emerge in children 
and young adults. 
 
METHODS: Subjects (n=3534) diagnosed with cancer under 30 years of age in 
Yorkshire between 1990 and 2005 were analysed. Differences in survival rates for 
diagnostic subgroups were estimated by ethnic group (south Asian or not) using Kaplan–
Meier estimation and Cox regression. 
 
RESULTS:  When compared to non-south Asians (all other ethnic groups excluding 
south Asians) a significant increased risk of death was seen for south Asians with 
leukaemia (hazard ratio (HR) = 1.75; 95% confidence interval (CI) = 1.11 to 2.76) and 
lymphoma (HR=2.05; 95%CI=1.09 to 3.87), whereas south Asians with solid tumours 
other than central nervous system tumours had a significantly reduced risk of death 
(HR=0.50 95%CI=0.28 to 0.89).  This was independent of socioeconomic deprivation.  
 
CONCLUSION: We found evidence of poorer survival outcomes for south Asians 
compared to non-south Asian children and young adults with leukaemia and lymphoma, 
but better outcomes for south Asian children and young adults with other solid tumours. 
This needs to be explained, and carefully addressed in the on-going development of 
cancer services. 
 
Keywords: Cancer; Epidemiology; Ethnicity; Paediatric; Survival 
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INTRODUCTION  
Cancer survival rates for children and young adults across Europe have improved 
markedly over recent decades, yet outcomes for certain types of cancers have been 
shown to vary by gender, age, treatment, place of care, geographical location and 
deprivation [1-4]. 
 
Within the UK, survival trends vary according to ethnic group across the adult age range. 
Worse survival rates from breast cancer have been observed amongst non-south Asian 
women (65-67% 5-year survival) compared to south Asian women (70-73% 5-year 
survival) [5-6]. However, it is unclear whether survival differences by ethnic group in the 
UK exist exclusively in the older adult population or whether they begin to emerge in 
childhood or young adults.  Survival rates for UK childhood cancer have shown few 
consistent patterns with ethnicity, although south Asians with acute lymphoblastic 
leukaemia (ALL) had a significantly higher risk of death compared to White children in 
one study [7], and a non-significantly higher risk in two studies [8-9]. In the US, the 
overall five year cancer survival rate of Hispanic children (72%) was found to be lower 
than for White children (84%), whilst another study shows Black children with ALL had 
poorer survival than White children (75% vs. 85%) [10-11]. However, this could be as a 
result of differences in socio-economic status affecting access to health care services in 
the US. Recent studies in Europe and England have reported on survival trends of 
teenage and young adult (TYA) cancer, however none have focused on differences by 
ethnic group [1,12].  
 
This study utilises high quality population–based data on children and young adults 
diagnosed with cancer between 1990 and 2005 in combination with a validated method 
of ethnicity assignment based on name analysis and linked hospital episode statistics 
(HES) data [13]. The specific aim was to investigate for the first time in the UK 
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differences and trends in cancer survival by ethnic group (south Asian or not) across the 
childhood (0–14) and young adult (15–29) age ranges.  
 
MATERIALS AND METHODS 
Case Data 
The data used for this study cover a 16 year period from 1990 to 2005 including all children 
and young adults under the age of 30, living in the former Yorkshire Regional Health 
Authority who were diagnosed with cancer other than skin carcinomas and melanomas. 
Cases were extracted from the population-based Yorkshire Specialist Register of Cancer in 
Children and Young People (YSRCCYP) [13]. 
  
Diagnoses were categorised into groups according to the International Classification of 
Childhood Cancer (ICCC); this histologically based classification scheme was chosen in 
preference to the site based classification used for adults [14], as the majority of our cases 
(54%) are aged 18 and under. In order to retain statistical power, diagnoses were grouped 
into four main categories; leukaemia, lymphoma, central nervous system (CNS) tumours, 
and other solid cancers, corresponding to ICCC codes I, II, III, and IV–XII. Biennial proactive 
follow–up of cases was carried out to ascertain each individual’s vital status, with a 
censoring date of 31st December 2009 so that all cases had a potential follow–up period of at 
least four years.  
 
The former Yorkshire region contained 11% of all south Asians under the age of 30 in 
England (Census, 2001) compared to only 7.4% of all 0–29 year old non–south Asians.  
 
Assignment of Ethnic Group 
Ethnicity was assigned as either south Asian (i.e. of Pakistani, Indian, or Bangladeshi origin) 
or non–south Asian (all other ethnicities) primarily via two name analysis programs (Nam 
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Pehchan and SANGRA) and secondly through an independent validation with linked 
inpatient HES data [13,15-16].   
 
Statistical Analysis 
Survival rates were examined overall and by major histological subtype to determine 
differences by ethnic group. Deprivation scores for address at diagnosis were derived using 
the Townsend index based on the 2001 Census. This electoral ward based measure of 
material wealth was derived as a composite score based on levels of unemployment, non–
home ownership, over-crowding, and non–car–ownership [17].  
 
Differences were initially assessed using Kaplan–Meier (KM) estimation and univariate log–
rank tests. Cox regression modelling was used to assess the independent impact of ethnic 
group on the survival time for all cancers combined and in each of the four main diagnostic 
groups adjusting for age, sex, year of diagnosis, deprivation, and stage of disease. A test for 
linearity was used to determine whether age and year were appropriately modelled as 
continuous variables. To differentiate between the independent effect of ethnicity and the 
potentially confounding effect of socioeconomic status, deprivation was adjusted for within 
each Cox model.  Deprivation was analysed as a continuous variable using Townsend 
scores. 
 
Stage at diagnosis was included in the analysis; instances where data on stage were 
unavailable were imputed using ordered logistic regression. White blood cell count was used 
as a proxy for stage when modelling leukaemia survival rates and missing values were 
imputed using linear regression. White blood cell count was log transformed to an 
approximately normal distribution.  Missing data on stage was assumed to be missing at 
random, as opposed to missing completely at random after interrogation of missing data 
patterns and comparisons of individuals with observed and missing data. Separate 
imputation models were created for all cancers combined and each main diagnostic group. 
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Each imputation model included the following variables; gender, age, year of diagnosis, 
deprivation level, ethnicity, treatment type, diagnostic group/subgroup, and relapse status. 
Interactions tested within the main analysis were also included within the imputation model 
(deprivation and ethnicity) [18]. Additionally, the Nelson–Aalen (NA) estimate of the 
cumulative hazard function and censoring indicator were included in the imputation model, to 
avoid underestimation of stage and survival time [19-20]. A total of 65 imputations were 
completed for each diagnostic group.  The results of each imputation were modelled 
individually using Cox regression and combined parameter estimates were calculated using 
Rubin’s rules [21]. All imputation methods were implemented in Stata 11 using multiple 
imputation by chained equations (MICE) [22-23].  
 
Hazard ratios (HR) were taken from the Cox regression models and reported for each 
covariate. In order to retain power, we considered separate Cox models for each major 
diagnostic group so that they adhered to the general rule of ten or more deaths per covariate 
[24]. Schoenfeld residuals were used to assess the Cox proportional hazards assumption for 
each imputation [25]. Random scatters around zero on plots of the residuals against the rank 
survival time by covariate validated these assumptions [26]. Furthermore, Monte Carlo (MC) 
standard errors were calculated to measure the level of uncertainty in all estimated 
quantities of each model, and the c–index measure of discrimination was used to assess 
predictive performance [27-28]. For each model estimate, MC errors were sufficiently small 
so that statistical significance remained unaltered at the upper and lower bounds and 
predictive power was above 70% in all cases.  Results from a complete-case analysis were 
compared to those from the multiple imputation analysis (see supplementary material).  
There were no important differences in terms of the direction of effects; however, there was 
an overall improvement in the precision of the analysis indicated by a reduction in standard 
errors. 
 
RESULTS 
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A total of 3534 children and young adults were registered with cancer between 1990 and 
2005 whilst living in the former Yorkshire region, of which 275 (7.8%) were south Asian 
(Table 1). We observed a total of 896 (27%) non-south Asian deaths compared to 80 (29%) 
south Asian deaths over the study period. The overall five year survival rate for both groups 
together was 75% (95% confidence interval (CI) 74–76%).  
 
Figure 1 contains univariate KM survival estimates for each main diagnostic group. Log-rank 
tests indicated no difference in survival rates between south Asians and non-south Asians 
for all cancers combined (p=0.27), lymphoma (p=0.23), CNS tumours (p=0.55), or other solid 
tumours (p=0.29). A significant difference was observed for leukaemia (p=0.02), with south 
Asians exhibiting consistently lower survival rates. The five year survival rate for south 
Asians with leukaemia was 60% (95%CI 47% to 71%) compared to 70% (95%CI 67% to 
74%) for non–south Asians. Univariate log–rank tests showed evidence of a significant 
difference in survival between diagnostic groups (p=0.001).  
 
KM estimates comparing 0–14 and 15–29 year olds by diagnostic group showed 15–29 year 
olds had significantly lower survival rates for leukaemia (p=0.001) and other solid tumours 
(p=0.001) but very little difference in survival rates for all cancers combined or lymphoma. 
No differences in survival rates were observed by gender.   
 
Cox Regression  
Data on stage of disease at diagnosis was missing in 66% overall, 66% for lymphoma cases, 
28% for CNS tumours, and 69% for other solid tumours. Additionally, white blood cell count 
was missing for 57% amongst leukaemia cases. There were no missing data in any of the 
other variables within the analysis. Missing values for stage of disease (and white blood cell 
count in case of leukaemia) were imputed.    
 
 8 
The results of the Cox proportional hazards modelling for all cancers combined and each 
main diagnostic group are given in Table 2, where each parameter estimate is mutually 
adjusted for all other covariates listed in the appropriate column. Overall for all cancers 
combined, there was no evidence of a significant difference in survival between south Asians 
and non-south Asians. However, significant differences in survival by ethnic group were 
observed amongst those with leukaemia, lymphoma, and other solid tumours. South Asians 
with leukaemia were 1.8 times more likely to die than non-south Asians, this difference was 
more apparent for 15–29 year olds (almost twice as likely), but was a consistent finding 
across diagnostic subgroups. South Asians with lymphoma were more than twice as likely to 
die compared to non–south Asians and this difference was most apparent amongst 0–14 
year olds, and was observed consistently for both Hodgkin’s disease (HD) and non–
Hodgkin’s lymphoma (NHL). Ethnicity did not demonstrate any independent effect on 
survival time amongst those with CNS tumours. For other solid tumours, south Asians were 
less likely to die by 50% compared to non–south Asians. This difference was particularly 
evident for sympathetic nervous system tumours, bone tumours, and sarcomas.  
 
We observed no significant differences in survival rates by gender for any diagnostic group. 
 
For all cancers combined, CNS tumours, and other solid tumours, there was a two to three 
percent significant increased risk of death for each single year in increase of age at 
diagnosis. We observed that older TYA diagnosed with leukaemia (aged 15–19, 20–24, and 
25–29 at diagnosis) were twice as likely to die compared to those in the youngest age group 
(0–4 years old). For lymphoma 10–14 year olds were half as likely to die compared to 25–29 
year olds. No significant differences were observed between the other age categories 
amongst this diagnostic group.  
 
 9 
Almost all diagnostic groups showed a consistent improvement in survival over time apart 
from other solid tumours. Significant improvements in survival since 1990 were observed for 
lymphoma and leukaemia (five and six percent per year respectively). 
 
There was no significant independent effect on survival by level of deprivation except for 
those diagnosed with lymphoma, such that increasing deprivation is associated with better 
survival rates. Since the south Asian population tends to live in more deprived areas, 
interactions between ethnicity and deprivation were tested in each model; however they 
were not statistically significant.  
 
For all cancers combined, leukaemia, CNS tumours, and other solid tumours survival rates 
were significantly lower in patients presenting with a more advanced stage of disease. There 
was no significant difference in survival rates of those with lymphoma according to stage of 
disease.   
 
DISCUSSION 
Our findings relate to a novel population-based study examining survival trends in relation to 
ethnic group encompassing the childhood, teenage and young adult age range. We 
observed significantly poorer survival outcomes for south Asians with leukaemia and 
lymphoma compared to non-south Asians, but improved survival for south Asians with other 
non-CNS solid tumours. The Yorkshire region is representative nationally in terms of its 
socioeconomic and demographic profile, and therefore our results can be easily generalised 
to the rest of the UK population [29]. Furthermore, an estimated 60% of the south Asian 
population within the study region originates from Mirpur in rural Pakistan, making it one of 
the few regions in the UK that allows for detailed analysis of a relatively homogeneous south 
Asian population [30]. 
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A few UK studies, including one from Yorkshire, have found evidence of survival inequalities 
occurring between ethnic groups in children under the age of 16 years [8-9]. However, our 
results describing the independent effects on survival of being south Asian ethnic origin, 
provide an important benchmark from which to judge the impact of the National Institute for 
Health and Clinical Excellence Improving Outcomes Guidance (IOG) for Children and Young 
People, due to be implemented by 2011 [31]. The public health implications and necessity to 
understand reasons for these discrepancies in survival are especially pertinent as we expect 
a three-fold increase of young people to be diagnosed with cancer who are of south Asian 
origin over the next 10-20 years [13]. 
 
Key observations were the statistically significant two-fold increased risk of death for south 
Asians with leukaemia and lymphoma in contrast to non–south Asians, as well as the 
significantly higher risk of death for non–south Asians with other solid tumours compared to 
south Asians. For other solid tumours this difference was seen across all ages, whereas for 
leukaemia it was most apparent amongst 15–29 year olds, and for lymphoma it appeared to 
be limited to patients aged 0–14 years; in all instances the effect remained significant even 
after adjustment for deprivation. For lymphoma, there was also an unexpected independent 
lower risk of death for individuals from more deprived areas. This may be due to subtle 
differences in the socioeconomic distribution between Indians, Pakistanis and Bangladeshis, 
or the use of an area based measure which may not necessarily reflect socioeconomic 
status at an individual level.  
 
In relation to survival and age at diagnosis, the data revealed that older patients, especially 
those aged 15–29 years, were significantly more likely to die than children under 15 years of 
age even after allowing for diagnostic group and stage/white cell count (acting as a proxy for 
stage) in the regression models. This increased mortality risk was seen for all cancers 
combined, leukaemia, CNS, and other solid tumours. Taken together with the increased risk 
of death associated with ethnicity, our results infer that south Asian patients aged 15–29 
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years with leukaemia would be four times more likely to die than non-south Asian children, 
under the assumption of multiplicative effects from the Cox regression modelling. Part of the 
explanation for lower survival rates seen in older children and young adults could be due 
either to differences in the biological or molecular characteristics of tumours occurring in this 
age group or the reported smaller proportion of older TYA patients (19% in 2006/2007) 
enrolled onto clinical trials than their childhood cancer counterparts (51% in 2006/2007) [32]. 
Efforts are underway in the UK to ensure all TYA have the opportunity to enter trials where 
appropriate and are treated within Principal Treatment Centres (PTC) so that individuals can 
be treated and followed-up within an environment with appropriate age and/or site-specific 
expertise.  
 
Limitations of our work included the relatively small number of south Asians in our study and 
therefore some lack of statistical power. Furthermore, stage at diagnosis was missing in two-
thirds of cases overall. However, multiple imputation was considered the best available 
option. Failure to include stage at diagnosis in the multivariate analysis could lead to bias in 
the results, whereas multiple imputation avoids discarding non-missing stage data or case 
wise deletion. Imputation for this level of missing values was considered acceptable because 
values were imputed for only one variable due to the availability of complete case data for all 
other variables included in the analysis. The use of multiple imputation is fast becoming an 
accepted statistical technique for handling missing data [33-34]. It has led to an improvement 
in precision of our estimates compared to a complete-cases analysis indicated by a 
reduction in standard errors by 44% on average.  
 
Importantly, survival rates showed a consistent improvement over the study period for 
leukaemia and lymphoma. However, such an improvement was not observed for all cancers 
combined, CNS tumours, or other solid tumours. 
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In summary, we found evidence of poorer survival outcomes of leukaemia and lymphoma 
associated with those of south Asian ethnic origin; particularly those aged over 15 years with 
leukaemia and under 15 years with lymphoma. Further work should focus carefully on the 
implementation and impact of the IOG for Children and Young People examining outcomes 
between ethnic minority groups across the UK. 
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FIGURE LEGENDS 
 
Figure 1: Kaplan–Meier (KM) estimates comparing south Asians and non–south Asians by 
diagnostic group 
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TABLES 
 
Table 1: Number of cases by diagnostic group, age, and gender for those diagnosed with 
cancer within Yorkshire, 1990–2005 
 
  
Number of Cases  
   
 
  South Asian Non-south Asian Total  P-value 
Diagnostic Group Cases (column %) Cases (column %) 
Leukaemia 66 (24%) 649 (20%) 715 
0.040 
Lymphoma 71 (26%) 689 (21%) 760 
CNS Tumours 37 (13%) 562 (17%) 599 
Other Solid Tumours 101 (37%) 1359 (42%) 1460 
     
 
Age at diagnosis (years) 
    
 
0-4 66 (24%) 650 (20%) 716 
0.743 
5-9 40 (15%) 364 (11%) 404 
10-14 37 (13%) 375 (12%) 412 
15-19 42 (15%) 463 (14%) 505 
20-24 41 (15%) 597 (18%) 638 
25-29 49 (18%) 810 (25%) 859 
     
 
Gender 
    
 
Male 159 (58%) 1995 (61%) 2154 
0.436 
Female 116 (42%) 1264 (39%) 1380 
     
 
Total  275 3,259 3534    
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Table 2: Hazard ratios (HR) and 95% confidence intervals (CI) from a Cox regression model 
for those diagnosed with cancer in Yorkshire, 1990-2005. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Variable Model 1: All cancers combined 
 
 Category HR (95% CI) 
Ethnicity NSA 1  
 
SA 0.86 (0.65-1.15) 
 
    
Gender Male 1 
 
Female 1.12 (0.97-1.30) 
 
    
Age at diagnosis 0-29 1.03 (1.02-1.03)** 
 
    
Year of diagnosis 1990-2005  0.94 (0.91-0.97)** 
 
    
Deprivation Townsend Score  1.02 (0.98-1.07) 
 
    
Stage of Disease
 a
 I 1 
 
 II  2.39 (1.44-3.97)** 
 
 III  7.32 (4.61-11.60)** 
 
 IV  8.20 (5.52-12.16)** 
 
    
Diagnostic Group Leukaemia 0.81 (0.59-1.09) 
 
Lymphoma 0.61 (0.48-0.78)** 
 
CNS tumours 1.58 (1.31-1.92)** 
 
 Other solid tumours  1 
*Significant at 5% level; **Significant at 1% level;
 a
Missing values for stage 
were imputed. Abbreviations CNS: central nervous system; NSA: Non-
south Asian; SA: south Asian  
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Table 3: Hazard ratios (HR) and 95% confidence intervals (CI) from Cox regression models for leukaemia, lymphoma, central nervous system tumours 
and other solid tumours, 1990–2005 
Variable Model 1a: Leukaemia Model 1b: Lymphoma Model 1c: CNS tumours Model 1d: Other solid tumours 
 
 Category HR (95% CI)  Category HR (95% CI)    Category HR (95% CI)  Category HR (95% CI) 
Ethnicity NSA 1  NSA 1  NSA 1  NSA 1  
 
SA 1.75 (1.10-2.76)* SA  2.05 (1.09-3.87)* SA 1.51 (0.82-2.78) SA 0.50 (0.28-0.89)* 
 
    
 
      
 
  
Gender Male 1 Male  1 Male 1 Male 1 
 
Female 1.03 (0.79-1.34) Female  1.21 (0.82-1.80) Female 1.00 (0.75-1.32) Female 0.97 (0.69-1.35) 
 
    
 
      
 
  
Age at diagnosis
a
 0-4 1 0-4 1.28 (0.65–2.51) 0-29  1.02 (1.01-1.04)** 0-29  1.03 (1.01-1.05)** 
 
5-9 0.70 (0.44–1.10) 5-9 0.66 (0.30–1.43) 
 
  
 
  
 
10-14 1.11 (0.68–1.80) 10-14 0.46 (0.23–0.92)* 
 
  
 
  
 
15-19 1.91 (1.24–2.96)** 15-19 0.77 (0.47–1.28) 
 
  
 
  
 
20-24 2.62 (1.67–4.13)** 20-24 0.86 (0.55–1.34) 
 
  
 
  
 
25-29 2.56 (1.62–4.03)** 25-29 1 
 
  
 
  
 
    
 
      
 
  
Year of diagnosis 1990-2005  0.94 (0.92-0.98)** 1990-2005  0.95 (0.91-0.99)* 1990-2005  0.99 (0.96-1.03) 1990-2005  1.01 (0.98-1.04) 
 
    
 
      
 
  
Deprivation   1.01 (0.97-1.05) 
 
0.94 (0.89-0.99)*   1.01 (0.96-1.05) 
 
1.03 (0.99-1.08) 
 
    
 
      
 
  
Stage of Disease
 b
 Log(WCC) 1.26 (1.05-1.51)* I 1 I 1 I 1 
 
    II 1.06 (0.32–3.50) II 2.72 (1.50–4.92)** II 4.73 (1.17-19.04)* 
 
    III 1.47 (0.51–4.28) III 9.95 (5.29–18.74)** III 19.11 (6.00-60.82)** 
 
    IV 2.87 (0.93–8.83) IV 13.72 (7.76–24.26)** IV 20.10 (6.91-58.44)** 
 
    
 
      
 
  
Diagnostic Subgroup ALL 1 HD 1 Ependymoma 1 Sympathetic NS 1 
AML 1.98 (1.45-2.72)** NHL 2.49 (1.10-3.84)** Astrocytoma 2.36 (1.31–4.24)* Renal 0.35 (0.18-0.68)** 
 
Other 0.87 (0.49-1.56) 
 
  PNET 0.79 (0.42–1.49) Malignant bone 0.57 (0.26-1.24) 
 
    
 
  Other Glioma 3.68 (1.87–7.23)** 
Soft-tissue 
sarcoma 0.73 (0.40-1.32) 
 
    
 
  Other 1.34 (0.64–2.81) Germ cell 0.19 (0.10-0.35)** 
              Other 0.45 (0.21-0.96)* 
 
*Significant at 5% level; **Significant at 1% level; 
a
Likelihood ratio test indicates evidence of non-linearity of age for leukaemia (p=0.001) and lymphoma (p=0.03); 
b
Missing values of stage 
were imputed, and white blood cell count was used as a proxy for stage in Model1a. Abbreviations ALL: acute lymphoblastic leukaemia; AML: acute myeloid leukaemia; CNS: central 
nervous system; HD: Hodgkin’s disease; NHL: non-Hodgkin’s lymphoma; NS: nervous system; NSA: non-south Asian; PNET: primitive neuroectodermal tumours; SA: south Asian; WCC: 
white blood cell count. 
